The Match Game (4.14.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.
Today, the CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids.
MMWR April 14, 2023
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that, at least for rheumatologists, payments from industry dried up as well.
During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.com
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.